. "Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors."@en . . . . . . . . . . . . . . . " "@en . . . . "AZD2563 is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of AZD2563, presumably due to negative trial results (though no results were reported)."@en . . . . "For the treatment of gram-positive infections, including multiresistant strains."@en . . . "investigational"@en . "# Ednie LM, Jacobs MR, Appelbaum PC: Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother. 2002 Jul;50(1):101-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12096013 # Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Sefton C: AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin Microbiol Infect. 2004 Mar;10(3):247-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15008947 # Howe RA, Wootton M, Noel AR, Bowker KE, Walsh TR, MacGowan AP: Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob Agents Chemother. 2003 Nov;47(11):3651-2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14576139"@en . . . "AZD2563 selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, AZD2563 binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process."@en . . . . "AZD2563"@en . . . . "252260-06-3"@en . . "Gram-positive Bacteria"@en .